Format

Send to

Choose Destination
Regen Med. 2017 Mar;12(2):203-216. doi: 10.2217/rme-2016-0112. Epub 2017 Feb 17.

The use of mesenchymal stromal cells in treatment of lung disorders.

Author information

1
Regenerative Medicine Cluster, Advanced Medical & Dental Institute (AMDI), Universiti Sains Malaysia, Bandar Putra Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia.
2
Stem Cell Biology & Regenerative Medicine, School of Pharmacy, University of Reading, Whiteknights, RG6 6UB Reading, UK.

Abstract

The therapeutic use of mesenchymal stromal cells (MSCs) represents a promising alternative clinical strategy for treating acute and chronic lung disorders. Several preclinical reports demonstrated that MSCs can secrete multiple paracrine factors and that their immunomodulatory properties can support endothelial and epithelial regeneration, modulate the inflammatory cascade and protect lungs from damage. The effects of MSC transplantation into patients suffering from lung diseases should be fully evaluated through careful assessment of safety and associated risks, which is a prerequisite for translation of preclinical research into clinical practice. In this article, we summarize the current status of preclinical research and review initial MSC-based clinical trials for treating lung injuries and lung disorders.

KEYWORDS:

cell-based therapy; lung disorders; mesenchymal stem cells; mesenchymal stromal cells; safety assessment

PMID:
28244823
DOI:
10.2217/rme-2016-0112
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center